Cardiology (all articles)
Review: Mechanical complications of acute myocardial infarction
11 Dec, 2020 | 09:19h | UTCMechanical Complications of Acute Myocardial Infarction: A Review – JAMA Cardiology
Videos: Acute Rupture of Left Ventricular Aneurysm AND Ventricular Septal Rupture AND Papillary Muscle Rupture
Global burden of cardiovascular diseases and risk factors, 1990–2019
10 Dec, 2020 | 09:00h | UTCNews Release: JACC: Cardiovascular Disease Burden, Deaths Are Rising Around the World – Institute for Health Metrics and Evaluation
Commentary on Twitter
A new #GBDstudy looks at global trends and the burden of cardiovascular diseases for 13 underlying causes and 9 related risk factors, and what this means for clinical practice and public health policy. Read more in @JACCJournals: https://t.co/7fsHnMKEg7 pic.twitter.com/ySLKICaBcZ
— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) December 9, 2020
A nationwide study in Denmark showed a higher than expected risk of cardiac events in patients with cancer receiving immune checkpoint inhibitors
10 Dec, 2020 | 08:49h | UTC
Review: Cardiopulmonary impact of particulate air pollution in high-risk populations
9 Dec, 2020 | 08:07h | UTC
Cohort study: In the general population, both low and high levels of LDL cholesterol were associated with an increased risk of all-cause mortality
9 Dec, 2020 | 08:11h | UTC
Commentary on Twitter
Studies on the association between LDL-C levels and the risk of all cause mortality have provided conflicting results. This new study investigates the association between levels of LDL-C and the risk of all cause and cause specific mortalityhttps://t.co/phsKXIgPfq
— The BMJ (@bmj_latest) December 8, 2020
Observational study: Even low dose oral glucocorticoids linked to increased cardiovascular risk in people with immune-mediated inflammatory diseases
8 Dec, 2020 | 07:35h | UTCCommentary: Patients receiving low dose steroid at increased risk of cardiovascular disease – Public Library of Science
Spironolactone use is associated with improved outcomes in patients with heart failure with preserved ejection fraction and concomitant resistant hypertension
8 Dec, 2020 | 07:44h | UTC
Randomized trial: High-dose influenza vaccine shows no additional benefit for heart disease patients
7 Dec, 2020 | 00:44h | UTCEditorial: Influenza Vaccine for Patients With High-risk Cardiovascular Disease
Commentary: High-dose influenza vaccine shows no additional benefit for heart disease patients – NIH News Releases
Commentary on Twitter
In patients w high-risk CVD, high-dose trivalent influenza vaccine, vs standard-dose quadrivalent vaccine, did not significantly reduce all-cause mortality or cardiopulmonary hospitalizations https://t.co/I3XygBajQL
— JAMA (@JAMA_current) December 4, 2020
Meta-analysis reinforces the safety of betablockers in patients with COPD and cardiovascular disease
6 Dec, 2020 | 23:30h | UTCCommentary: Beta-Blockers in Patients With COPD and CVD – American College of Cardiology
Short review: How to diagnose and manage radiation therapy cardiotoxicity
6 Dec, 2020 | 23:27h | UTCHow to Diagnose and Manage Radiation Cardiotoxicity – JACC: CardioOncology
Meta-analysis of statins for primary prevention: 100 adults (aged 50-75 years) without known cardiovascular disease would have to be treated for 2.5 years to prevent 1 major adverse cardiovascular event
30 Nov, 2020 | 00:56h | UTCEvaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis – JAMA Internal Medicine (link to abstract – $ for full-text)
Commentary: Time to Benefit of Statins for Primary Prevention of Cardiovascular Events – American College of Cardiology
Commentary on Twitter
It takes 2.5 years for the benefits of #statins to be seen. Frail older adults with life expectancy <2.5 years may be more likely to be harmed than helped by statins https://t.co/jbdW7bXopt
— JAMA Internal Medicine (@JAMAInternalMed) November 16, 2020
Practice recommendations for the management of the most common forms of secondary hypertension, including primary aldosteronism, renovascular hypertension, pheochromocytoma, Cushing’s syndrome, and sleep apnea
26 Nov, 2020 | 08:59h | UTC
Cohort study suggests there is no need to choose first-line drug treatment for hypertension according to age and ethnicity – guidelines could be simplified
26 Nov, 2020 | 08:56h | UTCCommentary: Study questions blood pressure drug guidance based on age and ethnicity – British Medical Journal AND Laurie Tomlinson: Shining a light into medicine’s dusty corners – The BMJ Opinion AND UK’s NICE Guidelines for Hypertension Tx Based on Age, Ethnicity May Need Updating – Physician’s Weekly AND
Commentary on Twitter
Current UK guidance on drug treatment for high blood pressure, which differs depending on a patient’s age and ethnicity, could be simplified in line with other international guidelines, suggests new @bmj_latest research @SarahJoSinnott https://t.co/bWLhXoFnV4
— The BMJ (@bmj_latest) November 21, 2020
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
23 Nov, 2020 | 09:46h | UTCKey perspectives: 2020 AHA/ACC Guideline for Hypertrophic Cardiomyopathy
News release: Hypertrophic cardiomyopathy guideline encourages shared decision-making – American College of Cardiology
Opinion: Improving care for heart failure with reduced ejection fraction—a potential polypill-based strategy
20 Nov, 2020 | 08:37h | UTC
#AHA20 [not published yet] Randomized trial: After drug-eluting stent implantation, one-month dual antiplatelet therapy (DAPT) followed by aspirin monotherapy was noninferior to 6-12 months of DAPT
19 Nov, 2020 | 09:21h | UTCCommentary: Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT – TCTMD
NICE Guideline: Acute coronary syndromes
19 Nov, 2020 | 09:24h | UTCAcute coronary syndromes – National Institute for Health and Care Excellence
Visual summary: STEMI
Visual summary: NSTEMI/unstable angina
Visual summary: Cardiac rehabilitation and secondary prevention
#AHA20 – Two studies show lower rate of atrial fibrillation recurrence with catheter cryoballoon ablation than with antiarrhythmic drug therapy
18 Nov, 2020 | 09:11h | UTCStudy 1: Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation – New England Journal of Medicine
Commentaries: EARLY AF and STOP AF Put Electrophysiology at a Crossroads – Medscape (free registration required) AND EARLY-AF: First-line Ablation Beats Meds for Recent Paroxysmal A-fib – TCTMD
Commentary on Twitter (thread – click for more)
NEJM published 2 RCTs of #AFib ablation vs AF drugs.
The rub was that the ablation was done EARLY in the course.
Practice had been to try drugs first then do ablation.
EARLY AF and STOP AF studied the procedure early. #AHA20 Thread and my column >>— John Mandrola, MD (@drjohnm) November 18, 2020
#AHA20 – Randomized trial: Among patients with recurrent pericarditis, Rilonacept was associated with lower risk of pericarditis recurrence than placebo
18 Nov, 2020 | 09:04h | UTCPhase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Rilonacept Prevents Recurrent Pericarditis: RHAPSODY – TCTMD AND Rilonacept inHibition of interleukin-1 Alpha and beta for recurrent Pericarditis: a pivotal Symptomatology and Outcomes stuDY – RHAPSODY – American College of Cardiology AND Trial shows drug effective in 96% of patients with recurrent pericarditis – Cleveland Clinic
Commentary on Twitter
Patients with recurrent pericarditis were treated with the interleukin-1 trap rilonacept. Those who had a response were randomly assigned to receive continued rilonacept or placebo. Rilonacept led to a significantly lower risk of pericarditis recurrence than placebo. #AHA20
— NEJM (@NEJM) November 17, 2020
#AHA20 – RCT: Sotagliflozin improved cardiovascular outcomes in patients with Diabetes and CKD. Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo
18 Nov, 2020 | 09:08h | UTCSotagliflozin in Patients with Diabetes and Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
#AHA20 – RCT: Sotagliflozin improved cardiovascular outcomes in patients with Diabetes and Recent Worsening Heart Failure. Diarrhea and severe hypoglycemia were more common with sotagliflozin than with placebo
18 Nov, 2020 | 09:06h | UTCSotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure – New England Journal of Medicine (link to abstract – $ for full-text)
The ‘Ten Commandments’ for the 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease
18 Nov, 2020 | 09:03h | UTCOriginal Guideline and commentary: 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease
Opinion: A new important study supports wider use of the polypill
18 Nov, 2020 | 09:01h | UTCRichard Smith: A new important study supports wider use of the polypill – The Lancet
Original study and commentaries: Randomized trial: A polypill comprising statins, multiple blood pressure lowering drugs, and aspirin prevents cardiovascular events among patients at intermediate cardiovascular risk
Commentary on Twitter
"We seem now to have good evidence that the polypill can reduce cardiovascular events and deaths by at least a third and probably by half in those who take the polypill regularly" @Richard56 discusses a new study in @NEJM https://t.co/B2tkN4pkDP
— The BMJ (@bmj_latest) November 17, 2020
#AHA20 – Randomized trial: In patients with atrial fibrillation and a bioprosthetic mitral valve, Rivaroxaban (20 mg) was noninferior to Warfarin (INR 2-3) for death, MACE, or major bleeding at 12 months
16 Nov, 2020 | 02:01h | UTCRivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Rivaroxaban may be as effective as warfarin for bioprosthetic mitral valves, AF – American Heart Association
Commentaries: Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib – TCTMD AND Rivaroxaban for Valvular Heart Disease and Atrial Fibrillation – RIVER – American College of Cardiology AND Rivaroxaban Noninferior to Warfarin for Atrial Fibrillation in Patients with Bioprosthetic Mitral Valves – NEJM Journal Watch
Commentary on Twitter
In a trial comparing rivaroxaban with dose-adjusted warfarin, rivaroxaban was noninferior to warfarin with respect to the mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months. #AHA20
— NEJM (@NEJM) November 14, 2020
#AHA20 – Randomized trial: A polypill comprising statins, multiple blood pressure lowering drugs, and aspirin prevents cardiovascular events among patients at intermediate cardiovascular risk
16 Nov, 2020 | 02:03h | UTCPolypill with or without Aspirin in Persons without Cardiovascular Disease – New England Journal of Medicine (link to abstract – $ for full-text)
News release: New study confirms combo pill alone and with aspirin lowers heart disease risk – American Heart Association
Commentaries: Polypill along with aspirin cuts heart attacks and strokes by up to 40%: International study – McMaster University AND Big study supports cheap combo pill to lower heart risks – Associated Press AND TIPS-3: International Study Looks at Benefits of Polypill and Polypill Plus Aspirin in Reducing CVD Risk – American College of Cardiology
Commentary on Twitter
Public health vs precision medicine. Thinking through a one size fits all drug prevention approach. "Combined Rx w/polypill+aspirin led to lower incidence of CV events than placebo among participants w/o CV disease who were at intermediate CV risk.” #AHA20https://t.co/TsbvPtA1Pl pic.twitter.com/Ylq3AKThII
— Harlan Krumholz (@hmkyale) November 14, 2020